Company Overview

AstraZeneca Canada Inc. is a wholly owned indirect subsidiary of AstraZeneca PLC with global headquarters in London, England. Shares of AstraZeneca PLC are traded publicly on the New York Stock Exchange, London Stock Exchange and Stockholm Stock Exchange under the symbol 'AZN'.

Established in April 1999, by a merger between Astra AB (Sweden) and Zeneca PLC (U. K.).

Research and Development

AstraZeneca is one of the leading pharmaceutical companies, both in Canada and worldwide, with a formidable product portfolio spanning seven major therapeutic areas: cardiovascular, gastrointestinal, oncology, pain control, respiratory, central nervous system and infection. AstraZenecas brands include Atacand, Losec, Zestril, Xylocaine, Arimidex, Pulmicort, Zomig and Seroquel. The Canadian headquarters and manufacturing facilities of AstraZeneca are located in Mississauga, Ontario, with a state-of-the-art basic research centre based in Montreal, Quebec.

AstraZeneca Canada Inc. is a research-driven company, which believes that curiosity is the best way to express their commitment to patient health. Looking beyond the obvious and solving problems in innovative ways - this is what drives the companys researchers forward in their hunt for new and better treatments for a wide array of medical conditions and diseases.

AstraZeneca Canada Inc. s fundamental commitment to research and development excellence is the foundation of the companys formidable product portfolio. Their success ratio in bringing new products to market is among the best in the pharmaceutical industry. Moreover, their wide range of products makes significant contributions to treatment options and patient care.

In Canada, AstraZeneca invests more than C$1.5 million every week on research and the pursuit of new therapies. At AstraZeneca R&D Montreal, more than 100 scientists are involved in conducting leading-edge basic research dedicated to pain treatment. Opened in 1997, the state-of-the-art research facility has already filed patents on new discoveries that AstraZeneca Canada Inc. hopes will improve the lives, not only of Canadians, but also of people around the world. Montreal is a cornerstone of the companys vision to become the global leader in the overall therapeutic area of pain control.

AstraZeneca Canada Inc. prides itself on being a leader in promoting research throughout Canada. The company is particularly proud of the AstraZeneca Research Award program, a multi-million dollar initiative operated in co-operation with the Canadian Institutes of Health Research, Canadas Research- Based Pharmaceutical Companies Research Program, and a number of national health organizations. The Research Award program is designed to fund research projects by up-and-coming scientists at universities and medical institutions across the country.

AstraZeneca Canada Inc. is also proud to sponsor seven chairs at four of Canadas leading universities. Such partnerships provide outstanding training opportunities for talented young researchers as well as world-renowned scientists. They also enable AstraZeneca Canada Inc. to strengthen its ties between industry and the leading-edge research of the Canadian academic community.

AstraZeneca Canada Inc. also pursues strategic research collaborations with external companies and academic institutions to support and enhance their drug discovery and development programs. As part of the medical affairs department at AstraZeneca Canada Inc., the research liaison team actively identifies and communicates information on novel Canadian research and technology to AstraZenecas global R&D group. In line with the overall drug discovery plan, areas of interest include pre-clinical investigation involving molecular biology, bioinformatics and combinatorial chemistry.

Company Information

Additional Details

Legal Name: AstraZeneca Canada Inc.

Number of Employees: 1500

Contacts

Services

• Bioremediation Services

  SPEL provides consulting services and laboratory studies in the areas of biotreatment and bioremediation. Areas covered include soil and groundwater and sediments as well as industrial effluents. Ex-situ and in-situ treatment approaches are included.

• Biotechnology

  Zeneca is a leading international bioscience company which creates new products and services to improve human health and nutrition and the quality of life. Zeneca's Sheridan park Environmental Laboratory (SPEL)is part of Zeneca's Environmental Service Team, whose primary role is to meet the environmental needs of Zeneca's businesses in North America and around the world. SPEL's focus is the development and application of technologies for remediating site contaminants. SPEL has been particularly active in developing bioremediation technologies for soils contaminated with chlorinated organics and other refractory organics. An increasing effort is being devoted to the development of in-situ remediation technologies.

  Proprietary remediation technology is available for licensing and SPEL also offers laboratory and consulting services to external companies.

Products

• Atropine, In Dosage, Human Use
• Calcium Therapy Preps, In Dosage, Human Use
• Dimenhydrinate, In Dosage, Human Use
• Epinephrine, In Dosage, Human Use
• Lidocaine, In Dosage, Human Use
• Potassium Chloride /Muriate Of Potash/
• Salt /Sodium Chloride/ Nes
• Water, Filtered, Sterilized, Purified
• Xenorem

  XENOREM is a proprietary bioremediation technology for treating soils contaminated with chlorinated and non-chlorinated pesticides and other chlorinated organics. The process employs indigenous organisms and agricultural and other amendments for the treatment. Careful control of environmental conditions is critical for successful treatment.

NAICS Categories

• 325410 Pharmaceutical and Medicine Manufacturing

Additional Information